SCHEMBL4855732

SCHEMBL4855732

CC(C)(C(=O)Nc1ccc(N2CCOCC2)cc1)c1ccc2c(c1)NC(=O)c1ccc(-c3cccc4cnccc34)cc1N2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 15/20 0.65
IKBKB O14920 1/20 0.65
CHEK2 O96017 1/20 0.47
KIT P10721 1/20 0.47
MARK3 P27448 1/20 0.47
MAPK1 P28482 1/20 0.47
AKT1 P31749 1/20 0.47
MARK2 Q7KZI7 1/20 0.47
AURKB Q96GD4 1/20 0.47
PDPK1 O15530 2/20 0.44
ROCK2 O75116 1/20 0.44
PRKX P51817 1/20 0.44
TNK2 Q07912 1/20 0.44
TRPV1 Q8NER1 1/20 0.41
KDR P35968 1/20 0.41
CSF1R P07333 1/20 0.40
MAPK14 Q16539 1/20 0.39
RORC P51449 1/20 0.39
AURKA O14965 1/20 0.38
JAK2 O60674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4855460 0.81 CHEK1 (0.65) CHEK1MARK3PDPK1ROCK2KDR
SCHEMBL4886321 0.80 CHEK1 (0.63) CHEK1IKBKBCHEK2KITMARK3
SCHEMBL4888868 0.80 CHEK1 (0.72) CHEK1IKBKBCHEK2KITMARK3
SCHEMBL4881049 0.80 CHEK1 (0.71) CHEK1IKBKBCHEK2KITMARK3
SCHEMBL4857152 0.80 CHEK1 (0.69) CHEK1IKBKBROCK2KDRCSF1R
SCHEMBL4850740 0.80 CHEK1 (0.69) CHEK1IKBKBROCK2KDRCSF1R
SCHEMBL4882434 0.79 CHEK1 (0.84) CHEK1IKBKBCHEK2KITMARK3
SCHEMBL4891936 0.78 CHEK1 (0.65) CHEK1IKBKBCHEK2KITMARK3
SCHEMBL4849487 0.78 CHEK1 (0.64) CHEK1IKBKBCHEK2KITMARK3
SCHEMBL5450351 0.77 CHEK1 (0.63) CHEK1IKBKBCHEK2KITMARK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US claimed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 CHEK1 38/4885IKBKB 358/4885CHEK2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.